Company: CERO
Filing Date: 2025-12-05
Form Type: S-1
Source: 0001213900-25-118817
Chunk: 106

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-12-05
Form: S-1
Chunk 106
---
 or lose; |

| ● | we may choose not to file a                                                                                                                
 patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual 
 property;                                                                                                                                  |

| ● | we may be required to change,                                                                                                        
 redesign or stop using trademarks, service marks, domain names, logos, trade names and other identifiers that we own or use to avoid 
 infringing the rights of third parties;                                                                                              |

| ● | we may fail to adequately protect 
 and police our trade secrets; or  |

| ● | the patents of others may have                                                                                                        
 an adverse effect on our business, including if others obtain patents claiming subject matter similar to or improving that covered by 
 our patents and patent applications.                                                                                                  |

Should any of these events occur, they could significantly harm our business, results of operations and prospects. Without patent protection on the composition of matter of our product candidates, our ability to assert our patents to stop others from using or selling our product candidates in a non-pharmaceutically acceptable formulation may be limited. Due to the patent laws of a country, or the decisions of a patent examiner in a country, or our own filing strategies, we may not obtain patent coverage for all of our product candidates or methods involving these candidates in parent patent applications. We may have to pursue divisional patent applications or continuation patent applications in the United States and other countries to obtain claim coverage for inventions which were disclosed but not claimed in parent patent applications. Moreover, it is possible that our pending patent applications will not result in granted patents, and even if such pending patent applications are granted as patents, they may not provide a basis for intellectual property protection of commercially viable products nor provide us with any competitive advantages. Further, it is possible that, for any of the patents that may be granted in the future, others will design around the patent rights or identify cancer treatment methods that do not concern the rights covered by our patent rights or licenses. Further, we cannot assure investors that other parties will not challenge any patents granted to us or that courts or regulatory agencies will hold our patents to be valid or enforceable. We also cannot guarantee that we will be successful in defending challenges made against our patents. Any successful third-party challenge to our patents could result in the unenforceability or invalidity of such patents, or to such patents being interpreted narrowly or otherwise in a manner adverse to our interests. Our ability to establish or maintain a technological or competitive advantage over our competitors may be diminished because of